Brogan Thomas V, Hall Matthew, Sills Marion R, Fieldston Evan S, Simon Harold K, Mundorff Michael B, Fagbuyi Daniel B, Shah Samir S
Seattle Children's Hospital, and Department of Pediatrics, Division of Critical Care Medicine, University of Washington School of Medicine, Seattle, Washington
Children's Hospital Association, Overland Park, Kansas.
Hosp Pediatr. 2014 Nov;4(6):348-58. doi: 10.1542/hpeds.2014-0045.
To describe readmissions among children hospitalized with H1N1 (influenza subtype, hemagglutinin1, neuraminidase 1) pandemic influenza and secondarily to determine the association of oseltamivir during index hospitalization with readmission.
We reviewed data from 42 freestanding children's hospitals contributing to the Pediatric Health Information System from May through December 2009 when H1N1 was the predominant influenza strain. Children were divided into 2 groups by whether they experienced complications of influenza during index hospitalization. Primary outcome was readmission at 3, 7, and 30 days among both patient groups. Secondary outcome was the association of oseltamivir treatment with readmission.
The study included 8899 children; 6162 patients had uncomplicated index hospitalization, of whom 3808 (61.8%) received oseltamivir during hospitalization, and 2737 children had complicated influenza, of whom 1055 (38.5%) received oseltamivir. Median 3-, 7-, and 30-day readmission rates were 1.6%, 2.5%, and 4.7% for patients with uncomplicated index hospitalizations and 4.3%, 5.8%, and 10.3% among patients with complicated influenza. The 30-day readmission rates did not differ by treatment group among patients with uncomplicated influenza; however, patients with complicated index hospitalizations who received oseltamivir had lower all-cause 30-day readmissions than untreated patients. The most common causes of readmission were pneumonia and asthma exacerbations.
Oseltamivir use for hospitalized children did not decrease 30-day readmission rates in children after uncomplicated index hospitalization but was associated with a lower 30-day readmission rate among children with complicated infections during the 2009 H1N1 pandemic. Readmission rates for children who had complicated influenza infection during index hospitalizations are high.
描述因甲型H1N1(流感病毒亚型,血凝素1型,神经氨酸酶1型)大流行性流感住院儿童的再入院情况,并进一步确定首次住院期间使用奥司他韦与再入院之间的关联。
我们回顾了2009年5月至12月期间向儿科健康信息系统提供数据的42家独立儿童医院的数据,当时甲型H1N1是主要的流感毒株。根据儿童在首次住院期间是否出现流感并发症将其分为两组。主要结局是两组患者在3天、7天和30天的再入院情况。次要结局是奥司他韦治疗与再入院之间的关联。
该研究纳入了8899名儿童;6162例患者首次住院无并发症,其中3808例(61.8%)在住院期间接受了奥司他韦治疗,2737例儿童患有复杂性流感,其中1055例(38.5%)接受了奥司他韦治疗。首次住院无并发症患者的3天、7天和30天再入院率中位数分别为1.6%、2.5%和4.7%,患有复杂性流感的患者分别为4.3%、5.8%和10.3%。无并发症流感患者中,30天再入院率在治疗组之间无差异;然而,首次住院有并发症且接受奥司他韦治疗的患者全因30天再入院率低于未治疗患者。再入院最常见的原因是肺炎和哮喘加重。
对于住院儿童,使用奥司他韦并未降低首次住院无并发症儿童的30天再入院率,但在2009年甲型H1N1大流行期间,与患有复杂性感染儿童的30天再入院率较低有关。首次住院期间患有复杂性流感感染的儿童再入院率较高。